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Rasmussen’s encephalitis (RE) is a rare and severe progressive epileptic syndrome with unknown
etiology. Infection by viruses, including human cytomegalovirus (HCMV), has been speculated to
be a potential  trigger for RE. However,  no viral  antigens have been detected in the brains of
patients with RE; thus, a possible clinical linkage between viral infections and RE has not been
firmly established. In this study, we evaluated the expression of HCMV pp65 antigen in brain
sections from 26 patients with RE and 20 non-RE patients by immunohistochemistry and in situ
hybridization, and assessed the associations between HCMV infection and clinical parameters.
Elevated expression of HCMV pp65 protein and DNA was observed in 88.5% (23/26) and 69.2%
(18/26) of RE cases, respectively. In the non-RE group, HCMV pp65 antigen was detected only in
two cases (10%), both of which were negative for DNA staining. Additionally, the intensity of HCMV
pp65 staining was correlated with a shorter duration of the prodromal stage, younger age of
seizure onset, and more severe unilateral cortical atrophy. Elevated expression of HCMV pp65 was
observed in  RE brain  tissue  and was  correlated  with  the  clinical  features  of  RE disease.  In
summary, our results suggested that HCMV infection may be involved in the occurrence and
progression of RE disease. Thus, further studies are needed to determine whether early treatment
with anti-HCMV antibodies could modulate the course of RE.
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INTRODUCTION
Rasmussen’s encephalitis (RE) is a rare, chronic, pro-
gressive neurological syndrome that often occurs in
childhood (Varadkar et al., 2014). The major clinical
characteristics of RE consist of focal epilepsy, progress-
ive hemiparesis, and the decline of cognitive function
(Bien et al., 2002b). Without surgical intervention, pa-
tients with RE eventually develop to a persistent status of
epilepsy, with more severe deterioration of neurological
function and cognitive impairment (Bien et al., 2002b).
Currently, hemispherectomy is the only effective treat-
ment for controlling seizures and cognitive deterioration
(Guan et al., 2014).
The etiology and pathogenesis of RE are unclear
(Varadkar et al., 2014). Several factors are thought to be
involved in the occurrence of this syndrome, including
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virus infection (Walter and Renella, 1989; Farrell et al.,
1991), autoantibodies (Rogers et al., 1994), cytotoxic T
cells (Bauer et al., 2002; Bien et al., 2002a), and abnor-
mal immune modulation (Luan et al., 2013; Luan et al.,
2016). Since various pathological characteristics ob-
served in the brains of patients with RE, such as lympho-
cyte infiltration, neuron loss, vascular cuffing, and mi-
crogliosis (Pardo et al., 2004), are similar to those ob-
served in viral encephalitis, virus infection has been pro-
posed to be an important cause of RE (Rasmussen et al.,
1958). This hypothesis was supported by data from pre-
vious studies in which nucleic acids of human cytomeg-
alovirus (HCMV), herpes simplex virus 1(HSV-1), and
Epstein-Barr virus (EBV) were detected in the brain tis-
sues of patients with RE by in situ hybridization or poly-
merase chain reaction (PCR), although viral antigen has
not been reliably detected (Walter and Renella, 1989;
Power et al., 1990; Jay et al., 1995). Moreover, Taka-
hashi et al. found that nearly 50% of patients with RE
had a prior history of infection or vaccination (Taka-
hashi et al., 2006), further supporting a role of virus in-
fection in RE. However, some researchers have failed to
detect viral components (Atkins et al., 1995). Therefore,
additional, more comprehensive investigations are
needed to identify the presence of viral antigens and nu-
cleic acids in the brain tissues of patients with RE, and
the clinical relevance of these findings needs to be care-
fully analyzed.
HCMV is a double-stranded DNA virus that belongs
to the family Herpesviridae. This virus contains approx-
imately 200 protein-coding genes, including pp65 and
immediate-early (IE) genes (Tandon and Mocarski,
2012). HCMV pp65 is the most abundant virion matrix
protein and is often used as an indicator of HCMV infec-
tion. HCMV was found to have a 70%–90% prevalence
in the general population and persists for the lifetime of
the host after primary infection (Britt, 2015). Approxi-
mately 30% of pregnant women experiencing primary
HCMV infection will transmit the virus to their develop-
ing fetuses during some stage of pregnancy, resulting in
a congenital HCMV infection rate of 1%–7% at birth
(Manicklal et al., 2013; Britt, 2015). Congenital HCMV
infection may either be asymptomatic or cause hearing
impairment, mental retardation, cerebral palsy, and neur-
on developmental disabilities (Manicklal et al., 2013).
Whether the childhood neurological disorder of RE pa-
tients has any link to HCMV infection is thus of consid-
erable sci-entific and clinical interest.
In the present study, we examined the expression of
HCMV pp65 protein and DNA in the brain tissues of 26
patients with RE and 20 control patients without RE. We
then analyzed the relationships between HCMV pp65 ex-
pression levels and clinical parameters. Our results will
provide important insights for further clarifying the role
of HCMV in the occurrence and progression of RE and
regarding the feasibility of anti-HCMV treatment in pa-
tients with RE.
MATERIALS AND METHODS
Patients, diagnosis, and sample collection
Twenty-six patients with RE, who were admitted to
Sanbo Brain Hospital from April 2008 to December
2013, were included in the study. The clinical diagnosis
was made according to the European diagnostic criteria
(Bien et al., 2005). The control group consisted of 20 pa-
tients who underwent surgical treatment for temporal
lobe epilepsy, generally matched with the RE patient
group for age at the time of surgery and seizure onset.
After craniotomy, at least two blocks of brain tissue from
different areas were collected from patients with RE. The
tissues were fixed, embedded in paraffin, sliced to 6-µm
thickness, and then used for pathohistological analysis
and HCMV detection. In the control group, brain samples
were obtained from the edges of the resected epilepto-
genic cortex.
Immunohistochemical staining (IHC)
After routine preparation, the tissue sections were heated
to 60 °C for antigen retrieval. Endogenous peroxidase
activity and nonspecific antibody binding sites were
blocked with 3% hydrogen peroxide and 1% bovine serum
albumin (BSA) in phosphate-buffered saline (PBS) with
0.05% Tween 20. Subsequently, the sections were incu-
bated with mouse anti-pp65 antibodies (ab49214, 1:200;
Abcam, Cambridge, UK) or mouse anti-IE1 antibodies
(ab65104, 1:40; Abcam) at 4 °C overnight. After wash-
ing, the sections were further incubated with secondary
antibodies (horseradish peroxidase [HRP]-conjugated
goat anti-mouse IgG). Finally, diaminobenzidine (DAB)
substrate was added for coloration. The sections were
then counterstained with hematoxylin and photographed
(Olympus X-cite 120; Olympus, Japan).
In situ hybridization (ISH)
For the detection of HCMV pp65 DNA in brain sections,
a digoxin-labeled DNA probe specific for pp65 (5′-
GCTCTTCTTTTTCGATATCGACTTGTTGCTGCAG
CG-3′), digoxin-labeled Alu DNA probe (positive con-
trol), and insect genomic DNA probe (negative control)
were purchased from Life Technologies (Eugene, USA).
For the ISH procedure, after pretreatment with pro-
teinase K (100 μg/mL) for 25 min at 37 °C, tissue sec-
tions were hybridized with the probes diluted using DIG
Easy Hyb (11603558001; Rochediagnostic, Indianapolis,
USA) at 95 °C for 20 min, followed by incubation for
16 h at 37 °C in a hybridization oven (UVP HL-2000
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Hybrilinker). After incubation with mouse anti-digoxin
IgG, the reaction was visualized by the addition of HRP-
conjugated goat anti-mouse IgG and DAB, and images
were acquired.
Scoring methodology of IHC and ISH
The IHC and ISH results were evaluated by following a
previously described scoring methodology (Luan and
Gao et al., 2013). Cells showing yellow or brown par-
ticles in the cytoplasm or nucleus were considered posi-
tive and were counted and analyzed using image analy-
sis software (Image-Pro Plus 6.0; Media Cybernetics
Inc., Bethesda, USA). The semiquantitative results were
expressed as the percentage of positive cells combined
with a subjective assessment of staining intensity, which
was scored as 0 (colorless), 1 (light yellow), 2 (yellow or
brown), or 3 (dark brown); the percentages of positive
cells were denoted as 0 (<5%), 1(5%–25%), 2 (26%–50%),
3 (51%–75%), or 4 (>75%). The product of the two
scores was used to evaluate the immunostaining results,
as follows: overall scores of ≤1, 2–3, 4–5, and > 6 were
defined as negative, weakly positive, moderately posit-
ive, and strongly positive, respectively.
Statistical analysis
Statistical analysis was performed using SPSS 17.0 soft-
ware. Chi square tests were performed to determine the
differences between the expression of HCMV compo-
nents in patients with or without RE. Student’s t tests and
check-board analyses were performed to determine the
differences in clinical features in subgroups of patients
with RE, according to the pp65 IHC intensity. Differ-
ences with P values of less than 0.05 were considered
statistically significant.
RESULTS
Clinical characteristics of patients with and
without RE
Twenty-six patients with RE were enrolled in this study,
including 16 girls (61.5%) and 10 boys (38.5%). Their
mean ages were 5.8 years (range: 1.2–18 years) and 7.5
years (range: 2.4–18.5 years) at seizure onset and at time
of surgery, respectively. History of infection and/or viral
vaccination prior to the seizure onset was observed in
14/26 (53.8%) patients. Eleven patients (42.3%) under-
went left-side surgery, including functional hemispherec-
tomy (FH), anatomic hemispherectomy (AH), and hemi-
sphere disconnection. The etiologies for the control
group consisted of ganglioglioma (n = 5), hippocampal
sclerosis (n = 8), and focal cortical dysplasia (n = 7). The
baseline comparison between RE and control groups is
shown in Table 1.
Magnetic resonance imaging (MRI) and
pathological findings in the brain tissues of
patients with RE
Mild to severe progressive unilateral multifocal cortical
atrophy around the sylvian fissure and diffuse subcorti-
cal hypersignal confined within the involved hemisphere
in the FLAIR sequence were observed in all patients
(Figure 1A, 1B). The pathological changes, including
pyknosis, loss of neurons, diffuse lymphocyte infiltra-
tion, perivascular lymphocyte cuffing, and glial cell prolif-
eration (Figure 1C, 1D), were observed in RE brain tissues.
However, no obvious morphological features of viral in-
clusion were observed.
Expression of HCMV components in the brain
tissues of patients with and without RE
Among the 26 patients with RE, 23 (88.5%) showed pos-
itive immunostaining for the HCMV pp65 protein. Among
these 23 cases, nine (34.6%) were strongly positive, nine
were moderately positive, and five (19.2%) were weakly
positive (Figure 2, Table 2). Similarly, HCMV pp65
DNA was detected in 69.2% (18/26) of RE samples;
among them, eight (30.8%), six (23.1%), and four
(15.4%) were strongly, moderately, and weakly positive,
respectively (Figure 3, Table 2). HCMV pp65 protein
was predominantly expressed in the cytoplasm of neuron-
like cells (Figure 2). In the control group, only two cases
(2/20, 10%) were weakly positive for pp65 antigen, and
all cases were negative for pp65 DNA (Figure 2, Table
2; P < 0.05 for both). Notably, all of the 18 HCMV pp65
DNA-positive RE samples were positive for HCMV
pp65 protein (Table 3). In other words, five IHC-posi-
tive patients with RE showed negative ISH staining, in-
Table 1. Clinical characteristics of patients with and without
RE 
RE (n = 26) Non-RE (n = 20)
Gender (female) 10 (38.5%) 12 (60%)
Preceding infection 14 (53.8%) 3 (6%)
Mean age at seizure
onset (years) 5.8 8.6
Mean age at surgery
(years) 7.5 14.8
Side of resection (left) 11(42.3%) 13 (65%)
Surgical method
FH 15 (46.2%) 0
AH 2 (15.4%) 0
Disconnection 9 (26.9%) 0
Lobectomy 0 20 (100%)
Note: FH: functional hemispherectomy; AH: anatomic
hemispherectomy
Yao Zhang et al.
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dicating that combined application of the two methods
may be necessary for enhancement of the detection rate.
Association between HCMV pp65 antigen
expression and the clinical parameters of
patients with RE
Based on the IHC intensity of HCMV pp65 antigen, pa-
tients with RE were divided into two groups: group A
with negative or weakly positive pp65 staining, and
group B with moderately or strongly positive pp65 stain-
ing. As shown in Figure 4, patients in group B showed a
shorter mean duration of the prodromal stage (17.9 ± 5.1
versus 4.6 ± 0.56 months, respectively; Figure 4A; P <
0.05) and a younger age at seizure onset as compared
with group A patients (4.5 ± 0.5 versus 7.4 ± 0.9 years,
respectively; Figure 4A; P < 0.01). Additionally, pa-
tients with RE with more intense HCMV pp65 staining
showed a more severe hemisphere cortical atrophy (Fig-
ure 4B; P = 0.037). There were no correlations between
the HCMV pp65 staining intensity and other clinical
parameters.
DISCUSSION
RE is now confirmed as an inflammatory autoimmune
neurological syndrome that can be triggered by exogen-
ous antigens and somehow mediated by Tlymphocyte
cytotoxicity as well as autoantibodies (Li et al., 1997;
Gahring et al., 2001; Bauer et al., 2002; Bien et al.,
2002a; Schwab et al., 2009). However, virus infection, as
an important potential initiating factor (Merkler et al.,
2006; Chen et al., 2016), has not been carefully studied.
In this study, we found significantly elevated pp65 ex-
pression in patients with RE in comparison with those in
the control group. Additionally, patients with RE show-
ing stronger pp65 staining exhibited a younger age of
disease onset, more rapid clinical course, and more
severe hemisphere atrophy compared with those having
weakly positive or negative pp65 staining. In combina-
tion with the frequent history of HCMV infection before
Figure 1.  MRI and pathological changes in the brains of
patients with RE Atrophy of the right hemisphere cortex
and widening of the sulcus (arrowheads) and caudate
nucleus (arrow) were noted before operation (A). Dif-
fuse hypersignal in the subcortical area (arrows, B). Mi-
croglial nodule formation in the cortex (arrow, C).
Lymphocyte infiltration and features of perivascular cuff
(arrow, D).
Figure 2.  Expression of HCMV pp65 protein in patients with RE The pp65 protein was detected by IHC. Representative
images are shown at low (200×, upper panels) or high (400×, lower panels) magnification. Positive staining of pp65 was
predominantly observed in the cytoplasm of cells (arrows).
Cytomegalovirus in RE
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RE onset, these results suggested a correlation between
the occurrence and development of RE and HCMV in-
fection.
Previously, several groups have detected nucleic acids
of EBV or HCMV in brain samples from patients with
RE by ISH and/or PCR (Walter and Renella, 1989), im-
plying the involvement of virus infections in RE devel-
opment and progression. However, there has been little
evidence of the presence of viral antigens in the brain tis-
sues of patients with RE, and no reports have demon-
strated thesignificant associations between the presence
of viral components and clinical parameters. In this
study, we detected, for the first time, not only a significantly
elevation of HCMV pp65 antigen and DNA in patients
with RE compared with that in controls, but also the as-
sociation between HCMV pp65 expression level in the
brain tissue and disease parameters inpatients with RE.
High levels of HCMV pp65 antigen in patients with RE
was closely related to a short duration of the prodromal
stage, more severe hemisphere atrophy, and younger age
at seizure onset. Therefore, our results, along with other
reports, have further supported the hypothesis that there
is a potential link between HCMV infections and dis-
ease progression of RE. However, additional studies are
needed to test this hypothesis. A previous study reported
no detection of HCMV, EBV, or HSV infections in seven
RE cases using ISH (Atkins et al., 1995). According to
reports and our experience, we believe that the reasons
for these discrepancies may be related to differences in
epidemiology, study populations, sample preparation,
and detection techniques as well as the small sample
sizes of the studies.
Table 2. Summary of IHC and ISH data for brain tissues of patients with and without RE 
IHC ISH
RE (n = 26) Non-RE (n = 20) RE (n = 26) Non-RE (n = 20)
Positive 23 (88.5%) 2 (10%) 18 (69.2%) 0
Strong 9 (34.6%) 0 8 (30.8%) 0
Moderate 9 (34.6%) 0 6 (23.1%) 0
Weak 5 (19.2%) 2 (10%) 4 (15.4%) 0
Negative 3 (11.5%) 18 (90%) 8 (30.8%) 20 (100%)
Figure 3.  Expression of HCMV pp65 DNA in patients with RE HCMV pp65 DNA was detected by ISH. Representative
images are shown at low (200×, upper panels) or high (400×, lower panels) magnification. Positive staining of pp65
DNA was predominantly observed in the cytoplasm and nucleus of cells (arrows).




ISH (positive) 18 0 18
ISH (negative) 5 3 8
Total 23 3 26
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The mechanism by which HCMV is involved in the
occurrence of RE is not well understood. HCMV and
other viruses detected in RE brain tissues are highly prev-
alent in the general population (Britt, 2015; Looker et al.,
2015). Since the average age of seizure onset in patients
with RE was 5.8 years, we speculated that congenital
and/or neonatal HCMV infections occurred in patients
with RE. HCMV pp65 is an abundant structural protein
of the virion and is often used as an indicator of the in-
fection. Generally, during primary infection, viral anti-
gens would be recognized by T cells, and a pool of memory
T cells would be formed. The responses from memory T
cells may damage neurons when being triggered by a
secondary virus infection after birth and thus, could be
linked to RE occurrence and progression. However,
more mechanistic studies are required to further clarify
how virus infection triggers the occurrence of RE.
In conclusion, elevated expression of antigen and nu-
cleic acid of HCMV pp65 was detected in the brain tis-
sues of patients with RE, and an abundance of HCMV
antigen was found to be correlated with the duration of
the prodromal stage, age of seizure onset, and hemi-
sphere atrophy. These results suggested that HCMV may
act as a trigger for RE and thereby participate in the oc-
currence and progression of RE. Additionally, antiviral
therapy may be a potential strategy for the prevention
and treatment of RE.
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